UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
September 23, 2004
(Date of earliest event reported)
Hubei Pharmaceutical Group Ltd.
(Exact name of registrant as specified in its charter)
NEVADA | |
000-25553 | |
88-0419476 |
(State or other jurisdiction
of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| |
410 Park Avenue, 15th Floor, New York, NY | |
10022 | |
| | (Address of principal executive offices) | | (Zip Code) | |
Registrant's telephone number, including area code: (604) 881-2899
| | [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | [ ] | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
| | [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition
On September 23, 2004 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated here in by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibit 99.1. Press release dated September 23, 2004
| | Exhibit Index |
| | 99.1 | Press release dated September 23, 2004 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Hubei Pharmaceutical Group Ltd.
(Registrant)
|
September 23, 2004
(Date) | | /s/ H. Y. (REID) LI
H. Y. (Reid) Li
President and Chief Executive Officer |
